Solborn Inc

Capital Structure and Liquidity Solborn Inc maintains a strong liquidity position with a current ratio of 5.25, indicating a robust ability to meet short-term obligations. The company's cash and equivalents amount to KRW 22,716,739,990, and its free cash flow stands at KRW 35,177,031,510, reflecting strong operational cash generation. The debt-to-equity ratio is 0.01, suggesting a conservative capital structure with minimal leverage. ### Profitability and Returns The company's profitability is evident with a net income of KRW 20,869,284,840 and an operating income of KRW 22,516,691,410. Return on equity (ROE) is 9.82%, and return on assets (ROA) is 5.57%, both of which are strong indicators of efficient capital utilization and profitability. These metrics align with the industry's preferred focus on ROE and ROA as key performance indicators. ### Segments and Geographic Exposure Solborn Inc's primary business is in the manufacturing and sale of medical imaging processing systems, with additional activities in software supply, real estate leasing, and investments in SMEs and venture companies. The company's revenue is primarily concentrated in South Korea, with no significant international exposure disclosed in the financial data. ### Growth Trajectory The company's growth trajectory is supported by its strong cash flow and profitability. While specific future revenue growth projections are not provided, the company's current financial health and operational efficiency suggest a stable and potentially growing business. The capital expenditure of KRW -527,510,480 indicates a focus on maintaining rather than expanding physical assets. ### Risk Factors The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's conservative capital structure and strong cash reserves mitigate financial risk. There is no indication of near-term dilution pressure, and the company's equity base is stable. ### Recent Events Recent events include the company's continued focus on its core medical imaging systems business, with no significant new product launches or strategic acquisitions disclosed in the latest financial filings. The company's recent financial performance and operational activities suggest a stable and well-managed business.